PubMed

First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation.

Zidek W, Schrader J, Lüders S, Matthaei S, Hasslacher C, Hoyer J, Bramlage P, Sturm CD, Paar WD.

Cardiovasc Diabetol. 2008 Jul 24;7:22.PMID: 18652658 [PubMed - indexed for MEDLINE]Related articlesFree article

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.

Scheen AJ.

Drugs. 2004;64(22):2537-65. Review.PMID: 15516153 [PubMed - indexed for MEDLINE]Related articles

Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project.

Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A; CAPPP Study Group.

Diabetes Care. 2001 Dec;24(12):2091-6.PMID: 11723089 [PubMed - indexed for MEDLINE]Related articlesFree article

Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.

Reboldi G, Gentile G, Angeli F, Verdecchia P.

Vasc Health Risk Manag. 2009;5(1):411-27. Review.PMID: 19475778 [PubMed - indexed for MEDLINE]Related articlesFree article

The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group.

Lièvre M, Marre M, Chatellier G, Plouin P, Réglier J, Richardson L, Bugnard F, Vasmant D.

Control Clin Trials. 2000 Aug;21(4):383-96.PMID: 10913814 [PubMed - indexed for MEDLINE]Related articles

The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.

Kuti EL, Baker WL, White CM.

Curr Med Res Opin. 2007 Jun;23(6):1239-44. Epub 2007 Apr 23.PMID: 17559720 [PubMed - indexed for MEDLINE]Related articles

Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors.

Mann JF.

Presse Med. 2005 Oct 22;34(18):1303-8. Review.PMID: 16269994 [PubMed - indexed for MEDLINE]Related articlesFree article

[DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease]

Scheen AJ.

Rev Med Liege. 2006 Oct;61(10):728-32. French. PMID: 17209507 [PubMed - indexed for MEDLINE]Related articles

The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension.

Meurin P.

Am J Cardiovasc Drugs. 2006;6(5):327-34. Review.PMID: 17083267 [PubMed - indexed for MEDLINE]Related articles

Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study.

Carroll CA, Coen MM, Rymer MM.

Clin Ther. 2003 Apr;25(4):1248-61.PMID: 12809971 [PubMed - indexed for MEDLINE]Related articles

Effectiveness and tolerability of fixed-dose combination enalapril plus nitrendipine in hypertensive patients: results of the 3-month observational, post-marketing, multicentre, prospective CENIT study.

de la Sierra A, Roca-Cusachs A, Redón J, Marín R, Luque M, de la Figuera M, Garcia-Garcia M, Falkon L; CENIT Study Working Group.

Clin Drug Investig. 2009;29(7):459-69. doi: 10.2165/00044011-200929070-00004.PMID: 19499963 [PubMed - indexed for MEDLINE]Related articles

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

Nephrol Dial Transplant. 2009 May;24(5):1663-71. Epub 2009 Jan 14.PMID: 19145003 [PubMed - indexed for MEDLINE]Related articles

The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy.

Khan NA, Hemmelgarn B, Herman RJ, Bell CM, Mahon JL, Leiter LA, Rabkin SW, Hill MD, Padwal R, Touyz RM, Larochelle P, Feldman RD, Schiffrin EL, Campbell NR, Moe G, Prasad R, Arnold MO, Campbell TS, Milot A, Stone JA, Jones C, Ogilvie RI, Hamet P, Fodor G, Carruthers G, Burns KD, Ruzicka M, DeChamplain J, Pylypchuk G, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Vallée M, Howlett J, Bacon SL, Lindsay P, Gilbert RE, Lewanczuk RZ, Tobe S; Canadian Hypertension Education Program.

Can J Cardiol. 2009 May;25(5):287-98. Review.PMID: 19417859 [PubMed - indexed for MEDLINE]Related articles

The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.

Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P; PHARAO Study Group.

J Hypertens. 2008 Jul;26(7):1487-96.PMID: 18551027 [PubMed - indexed for MEDLINE]Related articles

Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study.

Ogilvie RI, Anand S, Roy P, De Souza S; PEACH investigators.

Clin Drug Investig. 2008;28(11):673-86.PMID: 18840010 [PubMed - indexed for MEDLINE]Related articles

New-onset diabetes and antihypertensive drugs.

Mancia G, Grassi G, Zanchetti A.

J Hypertens. 2006 Jan;24(1):3-10. Review.PMID: 16331092 [PubMed - indexed for MEDLINE]Related articles

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.

Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S; ONTARGET investigators.

J Hypertens. 2009 Jul;27(7):1360-9.PMID: 19506526 [PubMed - indexed for MEDLINE]Related articles

[Antihypertensive pharmacotherapy of patients in primary care with either a statutory or private health insurance]

Laux G, Szecsenyi J, Miksch A, Grün B, Gutscher A, Grün B, Rosemann T, Kühlein T.

Med Klin (Munich). 2009 Feb 15;104(2):108-13. Epub 2009 Feb 26. German. PMID: 19242661 [PubMed - indexed for MEDLINE]Related articles

Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study.

Hathial M.

Indian Heart J. 2008 May-Jun;60(3):200-4.PMID: 19240307 [PubMed - indexed for MEDLINE]Related articles

The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus.

Burke TA, Sturkenboom MC, Ohman-Strickland PA, Wentworth CE, Rhoads GG.

Pharmacoepidemiol Drug Saf. 2007 Sep;16(9):979-87.PMID: 17605137 [PubMed - indexed for MEDLINE]Related articles